Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 26, 2026, 4:48 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 756 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Hypertension Ocular Clear all
Completed Phase 2 Interventional

A Study to Determine the Safety and Tolerability of 2 Concentrations of QLS-101

NCT04947124
View directory record Official record
Conditions
Sturge-Weber Syndrome (SWS), Glaucoma, Glaucoma Congenital, Ocular Hypertension
Interventions
QLS-101ophthalmic solution 1%, QLS-101ophthalmic solution 2%
Drug
Lead sponsor
Qlaris Bio, Inc.
Industry
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 19, 2025 · Synced Jun 26, 2026, 4:48 PM EDT
Completed Phase 3 Interventional

A 12-week, Randomized, Double-masked, Parallel Group Comparison of Evening Dosing With Xalacom in Subjects With Glaucoma

NCT00277498
View directory record Official record
Conditions
Open Angle Glaucoma, Ocular Hypertension
Interventions
Xalacom, Xalatan, Timolol
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
18 Years and older
Enrollment
528 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
64
States / cities
Birmingham, Alabama • Flagstaff, Arizona • Artesia, California + 52 more
Source: ClinicalTrials.gov public record
Updated Feb 17, 2021 · Synced Jun 26, 2026, 4:48 PM EDT
Recruiting Phase 2Phase 3 Interventional

Study of QLS-111-FDC in Open-Angle Glaucoma or Ocular Hypertension

NCT07354516
View directory record Official record
Conditions
OAG - Open-Angle Glaucoma, OHT - Ocular Hypertension
Interventions
QLS-111-FDC, Latanoprost (0.005%)
Combination Product · Drug
Lead sponsor
Qlaris Bio, Inc.
Industry
Eligibility
12 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Largo, Florida
Source: ClinicalTrials.gov public record
Updated Apr 2, 2026 · Synced Jun 26, 2026, 4:48 PM EDT
Not listed Not applicable Interventional

A Single Center Proof Of Concept Study To Assess Intra And Perioperative Safety Profile Of OMNI Surgical System

NCT04530084
View directory record Official record
Conditions
Open Angle Glaucoma
Interventions
OMNI Surgical System
Device
Lead sponsor
Mark Gallardo, MD
Other
Eligibility
22 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
El Paso, Texas
Source: ClinicalTrials.gov public record
Updated Aug 27, 2020 · Synced Jun 26, 2026, 4:48 PM EDT
Terminated Not applicable Interventional

Vision Preservation and Restoration Following a 6 Month Trial of GlaucoCetin

NCT04784234
View directory record Official record
Conditions
Primary Open Angle Glaucoma
Interventions
GlaucoCetin, Placebo
Dietary Supplement · Other
Lead sponsor
Wills Eye
Other
Eligibility
40 Years to 80 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 22, 2025 · Synced Jun 26, 2026, 4:48 PM EDT
Completed Phase 2 Interventional

Phase IIA Double-Masked Randomized Sham-Controlled Trial of QPI-1007 Delivered by a Single Intravitreal Injection to Subjects With Acute Primary Angle-Closure Glaucoma (APACG)

NCT01965106
View directory record Official record
Conditions
Glaucoma, Angle-closure, Primary, Acute
Interventions
QPI-1007 Injection, (including placebo)
Drug
Lead sponsor
Quark Pharmaceuticals
Industry
Eligibility
40 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
4
States / cities
Orange, California • Pasadena, California • Houston, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 6, 2017 · Synced Jun 26, 2026, 4:48 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Evaluation of the Bimatoprost Implant System Used in Combination With the SpyGlass Intraocular Lens Compared to Timolol Ophthalmic Solution

NCT06120842
View directory record Official record
Conditions
Cataract, Glaucoma, Ocular Hypertension
Interventions
Bimatoprost Implant System (High Dose), Bimatoprost Implant System (Low Dose), Timolol Maleate Ophthalmic Solution, 0.5%, Commercially Available Aspheric Monofocal Non-Yellow Chromophore IOL, SpyGlass IOL
Drug · Device
Lead sponsor
SpyGlass Pharma, Inc.
Industry
Eligibility
22 Years and older
Enrollment
201 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Glendale, Arizona
Source: ClinicalTrials.gov public record
Updated Aug 21, 2025 · Synced Jun 26, 2026, 4:48 PM EDT
Completed Not applicable Interventional

Intraocular Pressure Control Following One Site Versus Two Site Combined Phacoemulsification/IOL And Trabeculectomy

NCT00695747
View directory record Official record
Conditions
Glaucoma, Cataracts
Interventions
2 Site procedure- Phacoemulsification/IOL and Trabeculectomy
Procedure
Lead sponsor
Lahey Clinic
Other
Eligibility
Not listed
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2009
U.S. locations
1
States / cities
Burlington, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 21, 2009 · Synced Jun 26, 2026, 4:48 PM EDT
Completed Not applicable Interventional Results available

Educational Intervention to Adopt SLT as First-Line Glaucoma Treatment

NCT03365778
View directory record Official record
Conditions
Primary Open-angle Glaucoma
Interventions
Patient Educational Intervention, Usual Care, Ophthalmologist Educational Intervention
Other
Lead sponsor
Wills Eye
Other
Eligibility
40 Years to 90 Years
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 29, 2020 · Synced Jun 26, 2026, 4:48 PM EDT
Completed Not applicable Interventional

Glaucoma Management in the African-Derived Developing World Using Trabeculoplasty

NCT02375009
View directory record Official record
Conditions
Glaucoma
Interventions
Selective laser trabeculoplasty
Procedure
Lead sponsor
West Virginia University
Other
Eligibility
30 Years and older
Enrollment
129 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Morgantown, West Virginia
Source: ClinicalTrials.gov public record
Updated Jun 17, 2021 · Synced Jun 26, 2026, 4:48 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

The Detection of Glaucoma Using Pupillography

NCT01462526
View directory record Official record
Conditions
Glaucoma
Interventions
Not listed
Lead sponsor
Johns Hopkins University
Other
Eligibility
40 Years and older
Enrollment
798 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2016
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 11, 2017 · Synced Jun 26, 2026, 4:48 PM EDT
Completed Phase 3 Interventional Results available

DE-117 Spectrum 5 Study

NCT03697811
View directory record Official record
Conditions
Primary Open-angle Glaucoma and Ocular Hypertension
Interventions
DE-117 Ophthalmic Solution
Drug
Lead sponsor
Santen Inc.
Industry
Eligibility
18 Years and older
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
32
States / cities
Chandler, Arizona • Glendale, California • Mission Hills, California + 28 more
Source: ClinicalTrials.gov public record
Updated Aug 29, 2023 · Synced Jun 26, 2026, 4:48 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

AGN-193408 SR in the Treatment of Open-angle Glaucoma or Ocular Hypertension

NCT04499248
View directory record Official record
Conditions
Open-angle Glaucoma, Ocular Hypertension
Interventions
AGN-193408 SR, Lumigan, Sham Administration, Lumigan Vehicle
Drug · Other
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2029
U.S. locations
42
States / cities
Sun City, Arizona • Glendale, California • Inglewood, California + 38 more
Source: ClinicalTrials.gov public record
Updated May 21, 2026 · Synced Jun 26, 2026, 4:48 PM EDT
Completed Phase 3 Interventional Results available

A Phase III Study Assessing the Efficacy and Safety of DE-117 Ophthalmic Solution Compared With Timolol Maleate Ophthalmic Solution 0.5% in Subjects With Glaucoma or Ocular Hypertension - Spectrum 3 Study

NCT03691649
View directory record Official record
Conditions
Glaucoma and Ocular Hypertension
Interventions
DE-117 Ophthalmic Solution, Timolol Maleate Ophthalmic Solution 0.5%
Drug
Lead sponsor
Santen Inc.
Industry
Eligibility
12 Months and older
Enrollment
426 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
47
States / cities
Phoenix, Arizona • Sun City, Arizona • Burbank, California + 40 more
Source: ClinicalTrials.gov public record
Updated Aug 29, 2023 · Synced Jun 26, 2026, 4:48 PM EDT
Completed Not applicable Interventional

Endoscopic Goniotomy for Infantile Glaucoma

NCT00338533
View directory record Official record
Conditions
Glaucoma
Interventions
endoscopic goniotomy
Device
Lead sponsor
Vanderbilt University
Other
Eligibility
1 Week to 3 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2007
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 7, 2013 · Synced Jun 26, 2026, 4:48 PM EDT
Recruiting Phase 4 Interventional

24-hour Effect of Rocklatan Compared With Latanoprost in Open Angle Glaucoma and Ocular Hypertension Patients

NCT07325240
View directory record Official record
Conditions
Open Angle Glaucoma, Ocular Hypertension
Interventions
Netarsudil 0.02%/latanoprost 0.005% fixed dose combination ophthalmic solution, Latanoprost 0.005% Ophthalmic Solution
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 30, 2026 · Synced Jun 26, 2026, 4:48 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Effect of Age on Latanoprost 0.005% in Patients With Glaucoma

NCT00224289
View directory record Official record
Conditions
Glaucoma
Interventions
Latanoprost 0.005%
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2009
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Dec 9, 2012 · Synced Jun 26, 2026, 4:48 PM EDT
Completed Not applicable Interventional

Tolerability of an Anesthesia-free Tonometer Tip

NCT06585423
View directory record Official record
Conditions
Glaucoma
Interventions
Sterile commercially available bandage contact lens, Medical grade silicone of a thickness >100 µm, Medical grade silicone of a thickness <100 µm with blur tint, Standard tip in conjunction with a topical anesthetic
Diagnostic Test
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 8, 2026 · Synced Jun 26, 2026, 4:48 PM EDT
Completed Not applicable Interventional

How Safe and Effective is Micropulse Transscleral Cyclophotocoagulation in Patients With Uncontrolled Glaucoma?

NCT02627352
View directory record Official record
Conditions
Glaucoma
Interventions
Micropulse Transscleral Cyclophotocoagulation
Procedure
Lead sponsor
Wills Eye
Other
Eligibility
20 Years to 85 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 10, 2017 · Synced Jun 26, 2026, 4:48 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

A Universal Eye Drop Adherence Monitor to Measure and Improve Adherence to Ocular Medications

NCT03506568
View directory record Official record
Conditions
Medication Adherence, Glaucoma
Interventions
Devers Drop Device (D3) app
Device
Lead sponsor
Universal Adherence LLC
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Feb 20, 2023 · Synced Jun 26, 2026, 4:48 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

The Measurement of Intraocular Pressure in Normal Children Under General Anesthesia With and Without Nitrous Oxide and Anesthetic Eye Drops

NCT01925391
View directory record Official record
Conditions
Glaucoma, Intraocular Pressure, Anesthesia
Interventions
Tono-pen XL Applanation tonometer + Ocu-film +
Drug
Lead sponsor
University of Miami
Other
Eligibility
1 Year to 18 Years
Enrollment
75 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
2
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jun 15, 2014 · Synced Jun 26, 2026, 4:48 PM EDT
Recruiting Phase 4 Interventional

Rocklatan vs Latanoprost Post-DSLT

NCT07465913
View directory record Official record
Conditions
Glaucoma
Interventions
Rocklatan 0.02%-0.005% Ophthalmic Solution, Latanoprost 0.005% Ophthalmic Solution
Drug
Lead sponsor
Eye Centers of Southeast Texas
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Beaumont, Texas
Source: ClinicalTrials.gov public record
Updated May 21, 2026 · Synced Jun 26, 2026, 4:48 PM EDT
Completed Not applicable Interventional

An Open-Label Study of an Ophthalmic Solution to Reduce Intraocular Pressure in Patients With Ocular Hypertension

NCT00825396
View directory record Official record
Conditions
Ocular Hypertension
Interventions
C-KAD Ophthalmic Solution
Drug
Lead sponsor
Chakshu Research, Inc.
Industry
Eligibility
50 Years to 90 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Charlotte, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 10, 2009 · Synced Jun 26, 2026, 4:48 PM EDT
Completed Not applicable Interventional Results available

Study of OMNI System in OAG (GEMINI)

NCT03861169
View directory record Official record
Conditions
Open Angle Glaucoma
Interventions
Transluminal viscoelastic delivery and trabeculotomy
Device
Lead sponsor
Sight Sciences, Inc.
Industry
Eligibility
22 Years and older
Enrollment
209 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
15
States / cities
Dothan, Alabama • Lake Havasu City, Arizona • Fayetteville, Arkansas + 12 more
Source: ClinicalTrials.gov public record
Updated Aug 13, 2024 · Synced Jun 26, 2026, 4:48 PM EDT